Clinical Trials
34 trialsNCT02312102 2026-01-16
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT04490707 2022-03-24
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
Zhongda Hospital
Phase 3 Unknown
NCT01433965 2022-03-10
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
University of California, Davis
Phase 1 Completed
NCT00352365 2022-02-11
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01578954 2022-01-27
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00831766 2020-12-22
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01246622 2020-09-24
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT02472691 2020-05-28
AZALENA
Heinrich-Heine University, Duesseldorf
Phase 2 Completed
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT01629082 2019-12-17
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01743859 2019-10-08
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
University of Colorado, Denver
Phase 2 Completed
NCT01358734 2019-06-25
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT01904643 2018-10-29
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 1 Terminated
NCT00890929 2018-06-18
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Stanford University
Phase 1/2 Completed
NCT01442714 2018-01-03
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Phase 2 Terminated
NCT00466895 2017-11-14
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02255162 2017-08-18
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
Massachusetts General Hospital
Phase 1 Terminated
NCT01034592 2017-08-02
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Stanford University
Phase 1 Terminated
NCT01038635 2017-02-10
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01681537 2016-03-17
Lenalidomide Plus Chemotherapy for AML
Massachusetts General Hospital
Phase 1 Completed
NCT01301820 2016-03-16
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
French Innovative Leukemia Organisation
Phase 2 Completed
NCT01016600 2015-09-07
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT02525250 2015-08-17
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide
Institut Paoli-Calmettes
Phase NA Completed
NCT00957385 2015-06-19
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
University Health Network, Toronto
Phase 2 Completed
NCT00885508 2015-04-24
GFM-Chimio-Rev
Groupe Francophone des Myelodysplasies
Phase 2 Unknown
NCT01132586 2014-12-23
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00546897 2014-09-29
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Washington University School of Medicine
Phase 2 Completed
NCT00923234 2013-12-18
AZALE
Technische Universität Dresden
Phase 1 Terminated
NCT00720850 2013-09-27
LENAMAINT
Technische Universität Dresden
Phase 2 Terminated
NCT00360672 2013-08-14
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01556477 2012-03-16
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
Nordic MDS Group
Phase 2 Unknown
NCT00839059 2011-07-29
Lenalidomide In Patients With Acute Myeloid Leukemia
University of Ulm
Phase 1 Terminated